BRIEF—Tardive dyskinesia drug named CLSA's outstanding therapeutic

Ingrezza (valbenazine) capsules, the  first product approved for adults with tardive dyskinesia (TD), has been awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA).

Kevin Gorman, chief executive of Neurocrine Biosciences, the San Diego-based neurological and endocrine specialist behind Ingrezza, said: “The uncontrollable movements associated with tardive dyskinesia can leave people feeling isolated and stigmatized and now, with Ingrezza patients have an effective and convenient treatment option that can be taken while treating their underlying primary condition.

“We are pleased to be recognized by such a prestigious organization as CLSA and to be part of an impactful and dynamic community of innovators."